DUBLIN--(BUSINESS WIRE)--The "Respiratory Infection Diagnostic Markets by Technology, PLEX, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2020-2024" report has been added to ResearchAndMarkets.com's offering.
COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. In health facilities, clinics, physicians' offices and elsewhere. And let's not forget the screening market, not just for COVID, but for the rest of the 20 something respiratory pathogens as well. Multiplex vs single plex?
Explore the rapidly changing market as competitors jockey for position in new markets that are not yet well understood.
New technology is forever changing the diagnosis of respiratory infections. Shrinking time to result is opening up markets multiple times the size of current microbiology based practice. Diagnosis has already moved into the Emergency Room. It is now moving to the Physician's Office Lab. Could the Home be next?
The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress. The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory, already the largest infectious disease category could multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this in-depth report.
Key Topics Covered
i. Respiratory Infections Diagnostic Market - Strategic Situation Analysis and Impact of COVID-19
ii. Guide for Executives, Marketing, Sales and Business Development Staff
iii. Guide for Management Consultants and Investment Advisors
1. Introduction and Market Definition
1.1 What are Respiratory Infections?
1.2 The Role of Diagnosis & Treatment
1.3 Market Definition
1.3.1 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 A Spending Perspective on Clinical Laboratory Testing
1.5.1 An Historical Look at Clinical Testing
2. Market Overview
2.1 Players in a Dynamic Market
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Instrumentation Supplier
2.1.4 Distributor and Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Office Labs
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Respiratory Infections
2.2.1 Upper vs. Lower - Marketing Implications
2.2.2 Understanding the Role of Pneumonia
2.2.3 Bacterial Infections
2.2.3.1 Streptococcal Infections
2.2.3.2 Acute Otitis Media
2.2.3.3 Bacterial Rhinosinusitis
2.2.3.4 Diphtheria
2.2.3.5 Pneumococcal Pneumonia
2.2.3.6 Haemophilus Pneumonia
2.2.3.7 Mycoplasma Pneumonia (Walking Pneumonia)
2.2.3.8 Chlamydial Pneumonias and Psittacosis
2.2.3.9 Health Care-Associated Pneumonia
2.2.3.10 Pseudomonas Pneumonia
2.2.3.11 Pertussis (Whooping Cough)
2.2.3.12 Legionnaires Disease
2.2.4 Tuberculosis - A Special Case
2.2.5 Viral Infections
2.2.5.1 The Common Cold
2.2.5.2 Influenza
2.2.5.3 Viral Pneumonia
2.2.5.4 SARS and MERS
2.2.5.5 Measles (Rubeola)
2.2.5.6 Rubella (German Measles)
2.2.5.7 Chickenpox and Shingles
2.2.6 Fungal and Other Pathogens
2.2.6.1 Histoplasmosis
2.2.6.2 Coccidioidomycosis.
2.2.6.3 Blastomycosis
2.2.6.4 Mucormycosis
2.2.6.5 Aspergillosis
2.2.6.6 Pneumocystis Pneumonia
2.2.6.7 Cryptococcosis
2.3 Diagnostics - A Changing Role
2.3.1 Historical Practice
2.3.2 Current Diagnostics
2.3.3 The Multiplex Vector
2.3.4 Future Diagnostics - The Question of When and Where
2.3.5 Respiratory Infection Diagnostics - The Destination
2.3.6 Diagnostics as Defensive Weapons
3. Market Trends
3.1 Factors Driving Growth
3.1.1. Syndromic Multiplexing
3.1.2 T.A.T
3.1.3 Antimicrobial Resistance Movement
3.1.4 Pandemic Mitigation
3.1.5 An Aging at Risk Population
3.2 Factors Limiting Growth
3.2.1 The Cost Curve
3.2.2 Regulation and coverage
3.2.3 Laissez Faire
3.3 Instrumentation and Automation
3.3.1 The Shrinking Multiplexing Machine
3.3.2 Bioinformatics Networking and Anonymous Reporting
3.4 Diagnostic Technology Development
3.4.1 The Key Role of Time to Result
3.4.2 Single Cell Genomics Changes the Picture
3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.4 Pathogen Identification - A Projected Timetable of the Future
4. Respiratory Infection Diagnostics Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
- Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
- Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
- Qiagen Respiratory Panel with Coronavirus Receives CE Mark
- Lumos Diagnostics Closes $15M Series A Funding
- Fusion Genomics Wins $1M to Assess NGS-Based Respiratory Tract Infection Assay
- Coronavirus Detection Test Development by Co-Diagnostics
- Rapid Diagnostics Completes Asset Purchase of Enigma Diagnostics
- Flu-Like Epidemic Could Kill 80 Mn Globally
- Startup developing AI for TB detection
- Nipah Virus a Global Threat
- Novacyt S.A.: New Molecular Respiratory Panel Ready for US Market
- New DRC Ebola cases confirmed as FDA OKs rapid test
- CE Mark for Smartphone-based Diagnostic Test for Adult Respiratory Disease
- Curetis Submits Lower Respiratory Tract Infection Test for FDA Clearance
- New rapid test diagnoses pneumonia and other lower respiratory infections
- Ontera Awarded Contract for Zika Genotyping Test
- Two New Members Join Global Diagnostics Network
- BARDA Funding Health Security Solutions
5. Profiles of Key Players
- Abbott Diagnostics
- Accelerate Diagnostics
- Ador Diagnostics
- Akkoni Biosystems
- Alveo Technologies
- Applied BioCode
- Atlas Genetics
- Aus Diagnostics
- BD Diagnostics
- Biocartis
- BioFire Diagnostics
- bioMerieux
- Bio-Rad Laboratories
- Bosch Healthcare Solutions GmbH
- Cepheid
- Co-Diagnostics
- Cue Health
- Curetis
- Diagenode Diagnostics
- Diascopic
- Diasorin
- Expedeon
- Fusion Genomics
- GenePOC Diagnostics
- Genetic Signatures
- GenMark Dx
- Hologic
- Immunexpress
- Inflammatix
- Invetech
- Janssen Diagnostics
- Karius
- Lexigene
- Luminex
- Lumos Diagnostics
- Mammoth Biosciences
- Mbio Diagnostics
- Meridian Bioscience
- Mesa Biotech
- Mobidiag
- Nanomix
- Oxford Nanopore
- Panagene
- Primerdesign
- Prominex
- Qiagen (Statdx)
- Quantumdx
- Quidel
- Roche Molecular Diagnostics
- Saw Diagnostics
- Seegene
- Sensovation
- Siemens Healthineers (Fast Track Diagnostics).
- SkylineDx
- Sona Nanotech
- T2 Biosystems
- Thermo Fisher
- Veradus Labs
- Veramarx
6. The Global Market for Respiratory Infection Diagnostics
6.1 Global Market Overview by Country
6.1.1 Table - Global Market by Country
6.1.2 Chart - Global Market by Country
6.2 Global Market by Technology - Overview
6.2.1 Table - Global Market by Technology
6.2.2 Chart - Global Market by Technology - 2019/2024 Comparison
6.2.3 Chart - Global Market by Technology - 2019
6.2.4 Chart - Global Market by Technology - 2024
6.2.5 Chart - Global Market by Technology - Share by Year
6.3 Global Market by Plex - Overview
6.4 Global Market by Place - Overview
7. Global Respiratory Infection Diagnostic Markets - By Technology
7.1 Microbiology
7.1.1 Table Microbiology - by Country
7.1.2 Chart - Microbiology Growth
7.2 PCR
7.3 NGS
7.4 Immunoassay
7.5 Other
8. Global Respiratory Infection Diagnostic Markets - by Plex
8.1 Single Plex
8.1.1 Table Single Plex - by Country
8.1.2 Chart - Single Plex Growth
8.2 Duplex
8.3 Triplex
8.4 Multiplex Technology
9. Global Respiratory Infection Diagnostic Markets - by Place
9.1 Hospital Lab
9.1.1 Table Hospital Lab - by Country
9.1.2 Chart - Hospital Lab Growth
9.2 Outpatient Lab
9.3 POC
9.4 Other Technology
Appendices
I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
For more information about this report visit https://www.researchandmarkets.com/r/rxnplz
